Cyclodextrin News

August 14, 2025 Drug delivery / Pharma applications

Allopregnalonone/SBECD Complex in Clinical Trial for Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in Post Traumatic Stress Disorder

Clinical trial NCT07079761 may help us understand treatable factors that increase risk for chronic or treatment-resistant Post Traumatic Stress Disorder

March 21, 2019 Drug delivery / Pharma applications

Sage Therapeutics Announces FDA Approval of ZULRESSO™ (SBECD-enabled brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression

Approval based on results from three pivotal trials showing treatment with ZULRESSO provided significant and rapid reduction of depressive symptoms

November 17, 2018 Drug delivery / Pharma applications

Sage Therapeutics Announces FDA Advisory Committee Votes 17-1 in Support of Benefit-Risk Profile of ZULRESSO™ (brexanolone) Injection for Treatment of Postpartum Depression

If approved, ZULRESSO would be the first medicine specifically indicated for the treatment of postpartum depression (PPD) Sage Therapeutics (NASDAQ: